title: Ellagic acid antiinflammatory and antiapoptotic potential mediate renoprotection in cisplatin nephrotoxic rats.
abstract: Ellagic acid (EA) renoprotective effect against cisplatin (CIS)-induced nephrotoxicity remains elusive. Therefore, male Sprague-Dawley rats received CIS alone or EA (10 and 30 mg/kg, p.o.) for 5 days before and after CIS injection. CIS increased serum levels of blood urea nitrogen, creatinine, γ-glutamyl transferase, and reduced those of albumin and total protein. It also raised serum endothelin-1, as well as serum and renal nitric oxide, tumor necrosis factor-α, and monocyte chemoattractant protein-1. CIS enhanced the renal caspase-3, hemeoxygenase (HO)-1, nuclear factor-κB, and inducible nitric oxide. EA hampered CIS-induced nephrotoxicity manifested by an enhancement of the glomerular filtration rate which was associated by the reduction of inflammatory mediators and the apoptotic marker in the serum and/or kidney. The present study discloses that EA suppresses HO-1 and, its renoprotection is also linked to its anti-inflammatory and antiapoptotic properties, as well as the reduction of nitric oxide and endothelin-1.
authors.affiliation: Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, Egypt.
authors.forename: Amany M
authors.initials: AM
authors.lastname: El-Garhy
authors.forename: Ola M
authors.initials: OM
authors.lastname: Abd El-Raouf
authors.forename: Bahia M
authors.initials: BM
authors.lastname: El-Sayeh
authors.forename: Hala M
authors.initials: HM
authors.lastname: Fawzy
authors.forename: Dalaal M
authors.initials: DM
authors.lastname: Abdallah
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001806:Blood Urea Nitrogen; D053148:Caspase 3 / Q000187:drug effects / Q000378:metabolism; D018932:Chemokine CCL2 / Q000032:analysis / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D004610:Ellagic Acid / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood; D051547:Heme Oxygenase-1 / Q000378:metabolism; D007668:Kidney / Q000187:drug effects*; D008297:Male; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000187:drug effects; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D018932:Chemokine CCL2; D019332:Endothelin-1; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D004610:Ellagic Acid; D009569:Nitric Oxide; D003404:Creatinine; D051547:Heme Oxygenase-1; D005723:gamma-Glutamyltransferase; D053148:Caspase 3; D002945:Cisplatin
keywords: Apoptosis; Cisplatin; Ellagic Acid; Inflammation; Nephrotoxicity